EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Kantaro Biosciences, LLC has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit.
A Circular will today be sent to shareholders providing background to, details of and reasons for, a dividend in specie, to facilitate the spin-out of the Company’s shareholding in Trellus Health Limited to EKF’s shareholders.
Full year performance to further exceed market consensus
EKF to distribute Kantaro COVID-SeroKlir and COVID-SeroIndex quantitative COVID antibody tests in UK and Europe.
EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2020.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its interim results for the six months ended 30 June 2020 on Monday 14 September 2020.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.